August 22, 2019, Dresden, Germany — Due to their high accessibility and extensive beneficial properties, human Mesenchymal Stem Cells (hMSC) offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment. [Read more…]
GenCure announces breakthrough first run of 80-liter bioreactor
Biomanufacturing CDMO among first to harvest adult stem cells at large scale
SAN ANTONIO, Texas – In a breakthrough for the regenerative medicine industry, GenCure announced today that its biomanufacturing services team has successfully completed production runs expanding and harvesting human mesenchymal stem cells (hMSCs) in an 80-liter bioreactor. GenCure, a subsidiary of BioBridge Global (BBG), announced a major expansion of its biomanufacturing facilities in February of this year. [Read more…]
Biological Industries USA Adds Strategic Offering of Small Molecules to its Stem Cell Portfolio
August 8, 2019 — CROMWELL, Conn. — Biological Industries USA (BI-USA), a division of Biological Industries Beit Haemek Israel (BI), and provider of cell culture tools for translational research, today announced the addition and sale of small molecules for stem cell applications; specifically for enhancing research in diabetes, neural disorders, and cardiovascular disease.
Small molecules can be used to modulate biological signals for a multitude of applications, including cellular reprogramming, stem cell self-renewal, and the differentiation of stem cells into specific lineages, altogether advancing the rapidly evolving field of translational cell therapy. [Read more…]
Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley
Founded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.
In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory. [Read more…]
First iPSC-Derived CAR-T Therapy by CiRA and Takeda Nears Clinical Testing
− iCART Program Advances the Potential for a Highly Scalable, Lower Cost, Off-the-Shelf CAR T-Cell Therapy to Treat Cancer
KYOTO and OSAKA, Japan I July 16,2019 – The Center for iPS Cell Research and Application (CiRA) at Kyoto University and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that a novel induced pluripotent stem (iPS) cell-derived chimeric antigen receptor (CAR) T-cell therapy (iCART) has been transferred from their T-CiRA research collaboration to Takeda as the program begins process development toward clinical testing. Under the terms of the T-CiRA agreement, Takeda has the global rights to develop and commercialize the iCART product and CiRA will receive development and approval milestones. The teams will continue to collaborate as they prepare the iCART program for a clinical trial in 2021. [Read more…]
- « Previous Page
- 1
- …
- 102
- 103
- 104
- 105
- 106
- …
- 201
- Next Page »